ment of serious HSR. Indeed, comorbidities have been reported to increase the risk of HSR by at least 2.8 times, regardless of the type of IV-iron formulations (6).

**Conclusion**

It should be kept in mind that fatal AR related to FCM administration may develop, although rare. Therefore, FCM should be administered in centers where emergency treatment can be delivered by healthcare personnel who can evaluate and manage AR. It should be known that every administration bears AR risk, even if the previous treatment was well tolerated.

**References**

8. FDA-CDER. Injectafer (VIT-45, ferric carboxymaltose injection; FCM) for the treatment of iron deficiency anemia. Updated clinical safety information (last accessed 10 February 2020). Available at: URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203950Orig1s000MedR.pdf
10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury (last accessed 10 February 2020). Available at: URL: https://www.ncbi.nlm.nih.gov/books/NBK548069/
ercise. Her surface ECG showed “coupled-grouped beats” (Fig. 1) with a rate of approximately 134 beats per minute, but ICD recordings appeared to be ventricular tachycardia (VT). Atrial (A) and ventricular (V) signals seemed to be dissociated on the first look, but a constant relation existed between (V) and (A) signals, and the intervals between (V) signals were not equal. However, the next two R-R intervals were very close to each other, and an electrical alternans was also noticed by us (Fig. 2). VT and ventricular fibrillation zone cut-offs were 160 and 214 beats per minute, respectively. The patient was treated using anti-tachycardia pacing first and received biphasic shocks for the VT. Notably, supraventricular tachycardia (SVT) and VT discrimination criteria included electrogram morphology match, sudden onset, and interval stability. The interval stability was adjusted to 60 milliseconds (msec), and it was the most responsible parameter of false shocks despite a 3/3 match necessitating therapy.

The patient was referred for electrophysiological study. During sinus rhythm, the atrio-His1 (AH1), atrio-His2 (AH2), and His-ventricle intervals were 98, 420, and 45 msec, respectively, which demonstrated extremely elongated conduction of atrial signal over the slow pathway (Fig. 3).

Both atrioventricular re-entrant (AVRT) and atrioventricular nodal re-entrant (AVNRT) tachycardias were excluded through differential pacing maneuvers under isoproterenol infusion. Wenckebach AV conduction block developed at a drive train of 660 msec. Focal cryoenergy was delivered using Freezor XTRATM (Medtronic Inc. Minneapolis, MN, USA) catheter to the bottom of coronary sinus ostium to eliminate conduction over the slow pathway. Atrial signals were conducted to the ventricle over the fast pathway during ablation, and cryoenergy was delivered...
seven times for overall 1683 seconds. Additional 13 stimulations were performed after 30 minutes of ablation, but no tachycardia or dual response could be detected, and the clinical tachycardia was accepted as non-inducible.

The patient was treated with slow pathway ablation and has experienced no further palpitations or ICD therapies at 38 months of follow-up. Her LVEF improved to 50%–55% after 3 years of ablation. Her ICD reached elective replacement interval time after 38 months of ablation therapy, but no arrhythmia was noted on ICD recordings. Because of improved LVEF, absence of any arrhythmia and symptoms, the ICD battery was removed and decided not to be replaced with a new one.

Discussion

DAVNNT is a rarely published arrhythmia type and can often be misdiagnosed as atrial tachycardia, atrial fibrillation, VT, or premature ventricular contractions (2). Although the treatment of this arrhythmia is easy, the diagnosis can be challenging because of its highly mimicking features. Until date, DAVNNT has been the cause of tachycardia-induced cardiomyopathy in only eight patients (4-8). Atrial conduction over both slow and fast AV nodes is an underlying cause of this arrhythmia, which explains the double ventricular response to a single atrial signal. However, the absence of re-entry between slow and fast pathways makes it different from AVNRT. The effective refractory period and retrograde conduction features of the fast pathway may explain the underlying mechanism of DAVNNT. However, the precise clinical reason for this condition is not fully understood. Presumably, bad retrograde conduction feature of fast pathway and occurrence of AV block during a high drive train of ventricular stimulations could be the cause of DAVNNT.

Notably, AVNRT has a relatively difficult start and terminates in a short time. In contrast, DAVNNT starts easily in the presence of appropriate electrophysiological conditions and persists for long periods in few patients. In addition, the lower ventricular rate in DAVNNT and the absence of sudden onset and termination features of tachycardia, and nonexistence of well-defined surface ECG makes it challenging to detect it in daily practice. Unlike AVNRT, it increases the risk for tachycardia-induced cardiomyopathy because of its prolonged duration and similarities to sustained AT, AFL, and other incessant SVT.

The symptoms of our patient had started 15 years ago, and we believe that both tachycardia-induced cardiomyopathy and LBBB developed during this period. Based on the presence of LBBB, DAVNNT was misdiagnosed as VT and treated using ICD implantation. Per the literature, only few patients have been treated with ICD because of DAVNNT until now, and with one of them being diagnosed with sarcoidosis before, the exact reason for ICD implantation was unclear (9). However, our patient did not have any known cardiovascular diseases earlier, and the only cardiological problem was long-term, misdiagnosed, and untreated DAVNNT. Even though treatment guidelines have not considered ablation as the gold standard, it has been accepted as the most effective approach for treating DAVNNT. Moreover, this arrhythmia was alternatively treated using medication, and only one patient could be effectively treated, as noted on long-term follow-up (10). Furthermore, less information is available regarding the short-term, effective management of DAVNNT by using medication. One patient was deemed unsuitable for ablation and was successfully treated using propafenone for one day; however, the patient was lost to follow-up (11). The current patient was initially treated effectively with amiodarone, which could not be continued because of its side effects (12).

On the other hand, every second beat after P wave in our ECG could be evaluated as a premature ventricular contraction; however, the presence of almost the same morphology and axis of both consecutive QRS complexes excluded this probability. Furthermore, compensatory delay period in the sinus node activation and A-A intervals were not equal on the intracardiac electrogram recordings.

Conclusion

In summary, DAVNNT may be easily misdiagnosed as other complicated arrhythmias and lead to the unnecessary implantation of ICD. Furthermore, it can cause tachycardia-induced cardiomyopathy in certain patients, and the treatment of this arrhythmia plays a crucial role in the restoration of systolic functions. Therefore, we recommend that clinicians consider the possibility of DAVNNT in the presence of longstanding, mild cardiac symptoms, especially in cases where the number of QRS is more than P waves on surface ECG.

Informed consent: The informed written consent of the patient has taken by the clinician as a routine approach of our institution.

References

5. Li VH, Mallick A, Concanon C, Li VY. Wide complex tachycardia causing congestive heart failure. Pacing Clin Electrophysiol 2011; 34: 1154-7. [CrossRef]


12. Mádle A. A nonreentrant arrhythmia due to a dual atrioventricular nodal pathway. Int J Cardiol 1990; 26: 217–9. [CrossRef]